Unsafe
Not Aligned
Patient Risk:
High
Summary
Only a limited subset of claims (e.g., myalgia/myopathy and grapefruit increasing atorvastatin exposure) is supported by the provided label excerpts; many yoga/pose-specific and dehydration/CK-risk linkage claims are absent from the label and some safety-management statements are not grounded in the supplied labeling language.
Category Scores
Accurate Statements
Atorvastatin can cause myalgia.
Supported in provided label excerpt: Skeletal Muscle (5.1) describes muscle aches (myopathy) with CPK increases.
Atorvastatin can cause rare muscle damage.
Partially supported by provided label excerpt: Skeletal Muscle (5.1) reports rare cases of rhabdomyolysis.
Rhabdomyolysis is uncommon.
Partially supported by provided label excerpt: Skeletal Muscle (5.1) states rare cases of rhabdomyolysis.
Grapefruit juice ... can raise Lipitor blood levels ...
Supported directionally: Drug Interactions section 7.2 states grapefruit components inhibit CYP3A4 and can increase plasma concentrations of atorvastatin.
Unsupported Statements
Lipitor (atorvastatin) and yoga poses do not interact directly.
No label support in provided sections; label discusses drug interactions with other agents and skeletal muscle adverse effects, not exercise/poses.
Statins such as atorvastatin work through liver enzymes.
Mechanism wording is not supported by the provided excerpts as stated (the label excerpt provided is about HMG-CoA reductase inhibition, not the claim as phrased).
Atorvastatin does not change with physical postures.
No label support regarding effects of physical postures on atorvastatin pharmacokinetics.
Some users report greater soreness or stiffness after holding poses that load the legs and hips.
No label support for yoga-pose-specific symptom reports.
Holding poses that load the legs and hips may increase soreness or stiffness in some users.
No label support for yoga-pose-specific musculoskeletal symptom causation.
Deep squats increase muscle strain.
No label support; exercise modality not addressed in provided label excerpts.
Prolonged warrior poses increase muscle strain.
No label support; exercise modality not addressed in provided label excerpts.
Intense core holds increase muscle strain.
No label support; exercise modality not addressed in provided label excerpts.
When combined with Lipitor, deep squats, prolonged warrior poses, or intense core holds may heighten the chance of elevated creatine kinase levels.
No label support for yoga/pose-based CK risk escalation or any dose/behavioral interaction with CK.
Gentle modifications or shorter holds reduce this risk.
No label support for yoga modifications as a mitigation strategy for atorvastatin-associated skeletal muscle risk.
Severe muscle pain accompanied by dark urine may indicate rhabdomyolysis.
No label support in the provided excerpts explicitly linking this symptom pair to rhabdomyolysis diagnosis.
Rhabdomyolysis requires prompt attention.
Urgency wording is not present in provided excerpts; label advises discontinuation/withholding under specific circumstances and monitoring for muscle effects, but not the exact prompt-attention framing as stated.
Dehydration during yoga sessions can raise Lipitor blood levels and muscle risk.
No label support for dehydration during exercise raising atorvastatin concentrations or skeletal muscle risk.
Grapefruit juice consumed before class can raise Lipitor blood levels and muscle risk.
Label supports grapefruit increasing plasma concentrations of atorvastatin, but the timing 'before class' and 'muscle risk' framing tied to this timing is not specifically supported in the provided excerpts.
Avoiding grapefruit products on practice days reduces the risk of elevated Lipitor blood levels and muscle risk.
Label supports grapefruit increasing plasma concentrations, but does not provide counseling framed as 'practice days' or quantify risk reduction.
Pfizer’s key patents for Lipitor expired years ago.
Non-medical-label content; absent from provided label sections.
Generic atorvastatin is widely available.
Non-medical-label content; absent from provided label sections.
Statins such as atorvastatin work through liver enzymes.
While a liver-related mechanism is described in the label excerpt, the claim is not supported in the provided text as phrased (it is a broad, imprecise statement).
Contradictions
Important Omissions
Label-supported management steps for suspected/possible myopathy/rhabdomyolysis (e.g., discontinue if markedly elevated CPK or myopathy is diagnosed/suspected; temporarily withhold or discontinue in acute serious conditions or risk factors; consider closer monitoring in patients with renal impairment).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Yoga/pose- and dehydration-specific causal/PK/risk-escalation and risk-mitigation statements are not supported by the provided label. This could lead to inappropriate reliance on unlabeled activity-based factors instead of label-supported drug-specific risk management (myopathy/rhabdomyolysis monitoring, drug interaction risks, and discontinuation/withholding guidance).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple unlabeled, activity-specific and dehydration/CK-risk claims are presented as medication-related safety guidance without support from the provided FDA label excerpts.
Suggested Improvement
Remove yoga/pose-specific and dehydration/timing-based claims unless the label explicitly addresses them. Keep statements limited to label-supported risks (myopathy/rhabdomyolysis, risk factors like renal impairment, drug interaction risks) and label-supported counseling language (e.g., report unexplained muscle pain/tenderness/weakness; discontinue/withhold when criteria in the label are met; grapefruit can increase atorvastatin plasma concentrations, especially with excessive intake >1.2 L/day).